Deregulation of cannabis for medical purposes has led to significant recent interest and investment in the medical cannabis market in Europe. Investment in cultivation facilities, hydroponics, basic science and clinical research projects, manufacturing and distribution, and development of a CBD/wellness industry that didn’t exist previously present huge opportunities for established and start-up businesses and entrepreneurs, in the UK and globally.
Expert advice from our multi-disciplinary team
Our expertise in corporate law (including capital markets), life-sciences, regulatory matters, commodities, international trade and healthcare law, as well as our UK recognised litigation, employment, banking, property and tax teams supporting a company as it grows, uniquely positions the firm to advise established and start-up medical cannabis and CBD/wellness companies in the UK and Europe on regulation, licensing, research, manufacturing, distribution, capital raising, M&A and joint venture transactions in the medical cannabis and CBD/wellness industries.
The firm advises a number of larger established North American integrated companies, UK and European focused start-ups and joint ventures, as well as regulated institutions advising or raising capital for projects in the industry.
Our experience includes:
- advising FastForward Innovations Limited (AIM:FFWD) on the first medical cannabis investment by a UK-listed company since GW Pharma
- listing Sativa Investments Plc on the NEX Growth Market, the first listing of a medical cannabis-focused company in the UK since 1998
